On November 18, 2025, Arrowhead Pharmaceuticals, Inc. announced FDA approval of REDEMPLO (plozasiran) to help reduce triglycerides in adults with familial chylomicronemia syndrome. This event is significant for the company as it may enhance their market position and product offerings.